Vishnu Sunil Jaikumar
Higher Degree by Research Candidate
School of Pharmacy and Biomedical Sciences
College of Health
| Date | Position | Institution name |
|---|---|---|
| 2019 - 2022 | Veterinary Medical Officer | Rajiv Gandhi Centre for Biotechnology |
| 2016 - 2019 | Veterinarian and Research Associate III | Rajiv Gandhi Centre for Biotechnology |
| 2015 - 2016 | Veterinary Surgeon | Animal Birth Control for Dogs (ABCD) Kochi |
| 2014 - 2015 | Research Assistant | Kerala Veterinary and Animal Sciences University |
| 2014 - 2015 | Inpatient Unit Incharge | Kerala Veterinary and Animal Sciences University |
| Date | Type | Title | Institution Name | Country | Amount |
|---|---|---|---|---|---|
| 2024 | Award | FEBS Open Bio Poster Prize | ComBio 2024-Biomolecular Horizons 2024, Melbourne | Australia | - |
| 2012 | Scholarship | Kerala Veterinary and Animal Sciences University Assistantship | Kerala Veterinary and Animal Sciences University | India | - |
| 2012 | Award | Best Clinical Case Presentation Award | Madras Veterinary College, Tamil Nadu Veterinary and Animal Sciences University | India | - |
| Language | Competency |
|---|---|
| Divehi; Dhivehi; Maldivian | Can understand spoken |
| English | Can read, write, speak, understand spoken and peer review |
| Hindi | Can read, speak and understand spoken |
| Malayalam | Can read, write, speak and understand spoken |
| Tamil | Can speak and understand spoken |
| Date | Institution name | Country | Title |
|---|---|---|---|
| 2012 - 2015 | Kerala Veterinary and Animal Sciences University | India | Master of Veterinary Science |
| 2007 - 2012 | Rajiv Gandhi Institute of Veterinary Education and Research | India | Bachelor of Veterinary Science and Animal Husbandry |
| Date | Title | Institution name | Country |
|---|---|---|---|
| — | Certificate in Laboratory Animal Science (FELASA A,B,C,D) | Federation of European Laboratory Animal Science Associations | - |
| — | Certificate in Avian Medicine | QUADAM Institute | - |
| Year | Citation |
|---|---|
| 2026 | Rayginia, T. P., Keerthana, C. K., Aiswarya, S. U., Shifana, S. C., Jannet, S., Varma, S. S., . . . Anto, R. J. (2026). Orphan drug uttroside B impedes MASH progression and HCC development in experimental models. Jhep Reports, 8(2), 16 pages. |
| 2026 | Raj R, R., Datta, N., Krishnan U, S., Shanmugam, G., Louis, J. M., Jeyaram, R. D., . . . Maliekal, T. T. (2026). EPHA2-Ephrin-B1 cis-interaction drives an oncogenic reverse signaling, leading to the recurrence of oral cancer. Cell Communication and Signaling, 24(1), 300. |
| 2026 | Keerthana, C. K., Rayginia, T. P., Kalimuthu, K., Saha, S., Haritha, N. H., Nisthul Areekkara, A., . . . Anto, R. J. (2026). Uttroside B, a US FDA-designated ‘Orphan Drug’, mitigates the development of hepatocellular carcinoma and its pulmonary metastasis via EGFR/ERK-mediated inhibition of SREBP-1 and STAT-3. Cell Death Discovery, 12(1), 250. |
| 2025 | Das, D. J., Jaikumar, V. S., Suryaletha, K., Paul, M., Shankar, A., Nath, S. R., & Thomas, S. (2025). Probiotic Lacticaseibacillus paracasei from human gut microbiome against colistin-resistant Klebsiella pneumoniae: in vitro, in vivo and probiogenomic approaches. Beneficial Microbes, 16(4), 443-463. Scopus2 WoS2 Europe PMC2 |
| 2025 | Patra, D., Varghese, G. R., Jaikumar, V. S., Rajan, A., Krishnan, N., Kuppuswamy, K., . . . Srinivas, P. (2025). Decoding BRCA1 promoter hypermethylation: a new frontier in understanding sporadic breast cancer. Cancer Gene Therapy, online(12), 1-14. |
| 2024 | Nair, M. G., Mavatkar, A. D., Naidu, C. M., V. P, S., C. E, A., Rajarajan, S., . . . Prabhu, J. S. (2024). Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial–Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative Breast Cancer. Cells, 13(10), 24 pages. Scopus4 WoS4 Europe PMC3 |
| 2024 | Remadevi, V., Jaikumar, V. S., Vini, R., Krishnendhu, B., Azeez, J. M., Sundaram, S., & Sreeja, S. (2024). Urolithin A, induces apoptosis and autophagy crosstalk in Oral Squamous Cell Carcinoma via mTOR /AKT/ERK1/2 pathway. Phytomedicine, 130, 11 pages. Scopus15 WoS14 Europe PMC12 |
| 2023 | Thankamony, A. P., Ramkomuth, S., Ramesh, S. T., Murali, R., Chakraborty, P., Karthikeyan, N., . . . Nair, R. (2023). Phenotypic heterogeneity drives differential disease outcome in a mouse model of triple negative breast cancer. Frontiers in Oncology, 13, 13 pages. Scopus9 WoS7 Europe PMC7 |
| 2023 | Jayalekshmi, V. S., Jaikumar, V. S., Mehra, P., Thulaseedharan, T., Vinod, V. M., & Ramachandran, S. (2023). Differential expression of lipid metabolic genes in hypercholesterolemic rabbit placenta predisposes the offspring to develop atherosclerosis in early adulthood. Life Sciences, 327, 15 pages. Scopus4 WoS4 Europe PMC3 |
| 2023 | Richard, V., Nair, M. G., Jaikumar, V. S., Jones, S., Prabhu, J. S., & Kerin, M. J. (2023). Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators. International Journal of Molecular Sciences, 24(4), 3497. Scopus6 Europe PMC7 |
| 2023 | Vini, R., Jaikumar, V. S., Remadevi, V., Ravindran, S., Azeez, J. M., Sasikumar, A., . . . Sreeja, S. (2023). Urolithin A: A promising selective estrogen receptor modulator and 27-hydroxycholesterol attenuator in breast cancer. Phytotherapy Research, 37(10), 4504-4521. Scopus11 WoS9 Europe PMC10 |
| 2023 | Varghese, G. R., Patra, D., Jaikumar, V. S., Rajan, A., Latha, N. R., & Srinivas, P. (2023). βhCG mediates immune suppression through upregulation of CD11b+Gr1+ myeloid derived suppressor cells, CD206+ M2 macrophages, and CD4+FOXP3+ regulatory T-cells in BRCA1 deficient breast cancers. Immunology, 170(2), 270-285. Scopus6 WoS7 Europe PMC5 |
| 2022 | Riya, P. A., Basu, B., Surya, S., Parvathy, S., Lalitha, S., Jyothi, N. P., . . . James, J. (2022). HES1 promoter activation dynamics reveal the plasticity, stemness and heterogeneity in neuroblastoma cancer stem cells. Journal of Cell Science, 135(22), 16 pages. Scopus15 WoS16 Europe PMC13 |
| 2022 | Wanjale, M. V., Jaikumar, V. S., Sivakumar, K. C., Paul, R. A., James, J., & Kumar, G. S. V. (2022). Supramolecular Hydrogel Based Post-Surgical Implant System for Hydrophobic Drug Delivery Against Glioma Recurrence. International Journal of Nanomedicine, 17, 2203-2224. Scopus27 WoS25 Europe PMC19 |
| 2021 | Mukesh, R. K., Kalam, A. A., Nag, J., Jaikumar, V. S., Kunnakkadan, U., Kumar, N. A., . . . Johnson, J. B. (2021). Chandipura virus induces cell death in cancer cell lines of human origin and promotes tumor regression in vivo. Molecular Therapy Oncolytics, 23, 254-265. Scopus6 WoS6 Europe PMC6 |
| 2020 | Narendrakumar, L., Jaikumar, V. S., Chandrika, S. K., & Thomas, S. (2020). Epidemiological and pathogenic characteristics of Haitian variant V. cholerae circulating in India over a decade (2000–2018). Microbial Pathogenesis, 149, 10 pages. Scopus3 WoS3 Europe PMC3 |
| Year | Citation |
|---|---|
| 2025 | Padmaja, K. P., Mohan, A., Nair, M., Prabhu, J., Shabeer, H., Snijesh, V. P., . . . Maliekal, T. T. (2025). TIF1γ drives oral cancer recurrence by the transcriptional regulation of self-renewal genes, such as <i>HES1</i>. DOI |
| 2024 | Srinivas, P., Latha, N. R., Jaikumar, V. S., Varghese, G. R., Krithiga, K., Krishnan, N., . . . Patra, D. (2024). Targeting Ezrin Can Impede Transformation of Cancer Associated Fibroblast (Caf) to Metastasis Associated Fibroblasts (Maf) in Brca1 Defective Triple Negative Breast Cancers. DOI |
| 2024 | Rayginia, T., Keerthana, C., Aiswarya, S., Shifana, S., Jannet, S., Varma, S. S., . . . Anto, R. J. (2024). Uttroside B, a US-FDA-Designated Orphan Drug Against Hepatocellular Carcinoma (HCC), Impedes Non-alcoholic Steatohepatitis (NASH) and NASH -Induced HCC. DOI |
| 2022 | Thankamony, A., Murali, R., Chakraborty, P., Karthikeyan, N., Varghese, B. A., Jaikumar, V. S., . . . Nair, R. (2022). Phenotypic Heterogeneity Drives Differential Disease Outcome in Triple Negative Breast Cancer. DOI |
| 2022 | Nair, M., Apoorva, D., Chandrakala, M., Snijesh, V. P., Anupama, C. E., Rajarajan, S., . . . Prabhu, J. (2022). Acquisition of hybrid E/M phenotype associated with increased migration, drug resistance and stemness is mediated by reduced miR-18a levels in ER-negative breast cancer. DOI Europe PMC1 |
| 2022 | Patra, D., Varghese, G. R., Jaikumar, V. S., Rajan, A., Krishnan, N., Kuppuswamy, K., . . . Srinivas, P. (2022). BRCA1 Hypermethylation In Sporadic Breast Cancers: Discovering A Novel Pathway To Tumorigenesis Via Coordinate NBR2 Deregulation And TNBC Transformation. DOI |
Connect With Me
External Profiles
